Revance Therapeutics (RVNC) Stock Rating Upgraded by BidaskClub

Revance Therapeutics (RVNC) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Revance Therapeutics (NASDAQ:RVNC) from a strong sell rating to a sell rating in a research note published on Wednesday morning.

Several other research analysts have also recently weighed in on RVNC. Cantor Fitzgerald set a $50.00 price objective on Revance Therapeutics and gave the stock a buy rating in a research report on Tuesday, October 24th. Piper Jaffray Companies reissued a buy rating and issued a $28.00 price objective on shares of Revance Therapeutics in a research report on Friday, October 27th. Mizuho initiated coverage on Revance Therapeutics in a research report on Thursday, November 16th. They issued a buy rating and a $37.00 price objective on the stock. Barclays initiated coverage on Revance Therapeutics in a research report on Monday, November 27th. They issued an overweight rating and a $31.00 price objective on the stock. Finally, ValuEngine cut Revance Therapeutics from a hold rating to a sell rating in a research report on Monday, December 4th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $44.30.

Revance Therapeutics (RVNC) opened at $31.20 on Wednesday. Revance Therapeutics has a 1 year low of $18.00 and a 1 year high of $37.45. The firm has a market capitalization of $1,135.82, a price-to-earnings ratio of -8.21 and a beta of 1.36.

In other news, CEO L Daniel Browne sold 7,600 shares of the company’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total transaction of $189,544.00. Following the transaction, the chief executive officer now owns 133,188 shares of the company’s stock, valued at approximately $3,321,708.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 18.86% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Ameriprise Financial Inc. lifted its position in shares of Revance Therapeutics by 1.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,904 shares of the biopharmaceutical company’s stock valued at $604,000 after buying an additional 225 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Revance Therapeutics by 7.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,304 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 1,275 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Revance Therapeutics by 4.0% during the 4th quarter. Teachers Advisors LLC now owns 42,535 shares of the biopharmaceutical company’s stock valued at $1,521,000 after buying an additional 1,620 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Revance Therapeutics by 6.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 29,112 shares of the biopharmaceutical company’s stock valued at $769,000 after buying an additional 1,711 shares during the last quarter. Finally, Swiss National Bank lifted its position in shares of Revance Therapeutics by 7.9% during the 3rd quarter. Swiss National Bank now owns 35,450 shares of the biopharmaceutical company’s stock valued at $977,000 after buying an additional 2,600 shares during the last quarter. 77.84% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Revance Therapeutics (RVNC) Stock Rating Upgraded by BidaskClub” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/18/revance-therapeutics-rvnc-stock-rating-upgraded-by-bidaskclub.html.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

BidaskClub upgraded shares of Revance Therapeutics (NASDAQ:RVNC) from a strong sell rating to a sell rating in a research note published on Wednesday morning.

Several other equities research analysts also recently commented on RVNC. Cantor Fitzgerald set a $50.00 price objective on Revance Therapeutics and gave the company a buy rating in a report on Tuesday, October 24th. Piper Jaffray Companies restated a buy rating and set a $28.00 price objective on shares of Revance Therapeutics in a report on Friday, October 27th. Mizuho initiated coverage on Revance Therapeutics in a report on Thursday, November 16th. They set a buy rating and a $37.00 price objective for the company. Barclays initiated coverage on Revance Therapeutics in a report on Monday, November 27th. They set an overweight rating and a $31.00 price objective for the company. Finally, ValuEngine downgraded Revance Therapeutics from a hold rating to a sell rating in a report on Monday, December 4th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. Revance Therapeutics presently has an average rating of Buy and a consensus target price of $44.30.

Shares of Revance Therapeutics (NASDAQ RVNC) opened at $31.20 on Wednesday. The company has a market capitalization of $1,135.82, a P/E ratio of -8.21 and a beta of 1.36. Revance Therapeutics has a 1-year low of $18.00 and a 1-year high of $37.45.

In related news, CEO L Daniel Browne sold 7,600 shares of the company’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total transaction of $189,544.00. Following the completion of the sale, the chief executive officer now owns 133,188 shares in the company, valued at $3,321,708.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 18.86% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Ameriprise Financial Inc. grew its holdings in Revance Therapeutics by 1.0% during the second quarter. Ameriprise Financial Inc. now owns 22,904 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 225 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Revance Therapeutics by 7.5% during the second quarter. The Manufacturers Life Insurance Company now owns 18,304 shares of the biopharmaceutical company’s stock worth $483,000 after buying an additional 1,275 shares in the last quarter. Teachers Advisors LLC grew its holdings in Revance Therapeutics by 4.0% during the fourth quarter. Teachers Advisors LLC now owns 42,535 shares of the biopharmaceutical company’s stock worth $1,521,000 after buying an additional 1,620 shares in the last quarter. Parametric Portfolio Associates LLC grew its holdings in Revance Therapeutics by 6.2% during the second quarter. Parametric Portfolio Associates LLC now owns 29,112 shares of the biopharmaceutical company’s stock worth $769,000 after buying an additional 1,711 shares in the last quarter. Finally, Swiss National Bank grew its holdings in Revance Therapeutics by 7.9% during the third quarter. Swiss National Bank now owns 35,450 shares of the biopharmaceutical company’s stock worth $977,000 after buying an additional 2,600 shares in the last quarter. Institutional investors and hedge funds own 77.84% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/18/revance-therapeutics-rvnc-stock-rating-upgraded-by-bidaskclub.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply